Literature DB >> 33147331

Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.

Calixto-Hope G Lucas1, James P Grenert1,2, Andrew Horvai1.   

Abstract

CONTEXT.—: Dedifferentiated chondrosarcoma is a rare adult bone tumor with a dismal prognosis and is composed of a conventional chondrosarcoma juxtaposed to high-grade nonchondrogenic sarcoma. Dedifferentiated chondrosarcomas may represent tumor progression from a differentiated to a primitive histotype. OBJECTIVE.—: To determine the genetic and molecular events that drive progression from a conventional chondrosarcoma to high grade nonchondrogenic sarcoma. DESIGN.—: We analyzed the genomic landscape of paired conventional and dedifferentiated components of 11 dedifferentiated chondrosarcoma using targeted next-generation DNA sequencing with immunohistochemical validation. Clinical, radiographic, and pathologic features of tumors were reviewed. Capture-based DNA sequencing targeting the coding regions of 479 cancer genes and select introns was performed. RESULTS.—: The tumors arose in the femur (n = 4; 36%), scapula (n = 3; 27%), pelvis (n = 3; 27%), and humerus (n = 1; 9%) of 7 men (64%) and 4 women (36%; median age, 61 years). DNA was adequate for sequencing from all 11 dedifferentiated components (100%) and 9 paired conventional chondrosarcoma components (82%). All tumors (100%) harbored either IDH1 p.R132 or IDH2 p.R172S hotspot mutations. Seven tumors (64%) displayed COL2A1 alterations. TERT promoter mutations were present in 5 of 9 pairs (56%) and 2 (22%) additional unpaired dedifferentiated components. IDH1/2, COL2A1, and TERT mutations were identical in both components of the paired samples. Pathogenic missense or truncating mutations in TP53 and large-scale copy number alterations were more common in dedifferentiated components than in those of matched conventional components. CONCLUSIONS.—: The results support IDH1/2, COL2A1, and TERT promoter mutations being common in dedifferentiated chondrosarcoma and as likely early events in progression, whereas inactivating mutation of TP53 and high-level copy number alterations may be later events in the dedifferentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33147331     DOI: 10.5858/arpa.2020-0379-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.686


  3 in total

1.  Dedifferentiated chondrosarcoma of the ring finger: a case report of an exceptional surgical treatment and review of literature.

Authors:  Olimpia Mani; Lorenzo Andreani; Antonio D'Arienzo; Simone Colangeli; Rodolfo Capanna
Journal:  Orthop Rev (Pavia)       Date:  2022-04-25

2.  Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.

Authors:  Huy Gia Vuong; Tam N M Ngo; Ian F Dunn
Journal:  Cancer Med       Date:  2021-06-03       Impact factor: 4.711

3.  A genetic model for central chondrosarcoma evolution correlates with patient outcome.

Authors:  Peter Van Loo; Adrienne M Flanagan; William Cross; Iben Lyskjær; Tom Lesluyes; Steven Hargreaves; Anna-Christina Strobl; Christopher Davies; Sara Waise; Shadi Hames-Fathi; Dahmane Oukrif; Hongtao Ye; Fernanda Amary; Roberto Tirabosco; Craig Gerrand; Toby Baker; David Barnes; Christopher Steele; Ludmil Alexandrov; Gareth Bond; Paul Cool; Nischalan Pillay
Journal:  Genome Med       Date:  2022-08-30       Impact factor: 15.266

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.